Themis Medicare Limited (THEMISMED) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.004x

Based on the latest financial reports, Themis Medicare Limited (THEMISMED) has a cash flow conversion efficiency ratio of -0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-14.84 Million ≈ $-160.49K USD) by net assets (Rs3.80 Billion ≈ $41.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Themis Medicare Limited liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Themis Medicare Limited - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Themis Medicare Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Themis Medicare Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Themis Medicare Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Samil Pharm
KO:000520
0.016x
Nordhealth AS
OL:NORDH
-0.008x
New Delhi Television Limited
NSE:NDTV
1.199x
Netas Telekomunikasyon AS
IS:NETAS
0.222x
Oroco Resource Corp
V:OCO
-0.014x
Spheria Emerging Companies Ltd
AU:SEC
0.041x
Alpha Astika Akinita S.A
AT:ASTAK
-0.330x
Novus Holdings Ltd
JSE:NVS
0.038x

Annual Cash Flow Conversion Efficiency for Themis Medicare Limited (2006–2025)

The table below shows the annual cash flow conversion efficiency of Themis Medicare Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Themis Medicare Limited worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs4.03 Billion
≈ $43.54 Million
Rs347.10 Million
≈ $3.75 Million
0.086x +47.37%
2024-03-31 Rs3.78 Billion
≈ $40.84 Million
Rs220.94 Million
≈ $2.39 Million
0.059x +23.40%
2023-03-31 Rs3.39 Billion
≈ $36.71 Million
Rs160.93 Million
≈ $1.74 Million
0.047x -60.37%
2022-03-31 Rs2.87 Billion
≈ $31.09 Million
Rs343.94 Million
≈ $3.72 Million
0.120x -54.12%
2021-03-31 Rs2.19 Billion
≈ $23.63 Million
Rs569.75 Million
≈ $6.16 Million
0.261x +14440.88%
2020-03-31 Rs1.83 Billion
≈ $19.79 Million
Rs3.28 Million
≈ $35.49K
0.002x -97.41%
2019-03-31 Rs1.58 Billion
≈ $17.09 Million
Rs109.23 Million
≈ $1.18 Million
0.069x +48.70%
2018-03-31 Rs1.69 Billion
≈ $18.26 Million
Rs78.47 Million
≈ $848.62K
0.046x +152.43%
2017-03-31 Rs1.20 Billion
≈ $13.03 Million
Rs-106.78 Million
≈ $-1.15 Million
-0.089x -128.86%
2016-03-31 Rs788.89 Million
≈ $8.53 Million
Rs242.32 Million
≈ $2.62 Million
0.307x +0.33%
2015-03-31 Rs589.08 Million
≈ $6.37 Million
Rs180.34 Million
≈ $1.95 Million
0.306x +188.73%
2014-03-31 Rs561.85 Million
≈ $6.08 Million
Rs59.57 Million
≈ $644.27K
0.106x +25.17%
2013-03-31 Rs537.17 Million
≈ $5.81 Million
Rs45.51 Million
≈ $492.12K
0.085x +132.21%
2012-03-31 Rs580.79 Million
≈ $6.28 Million
Rs-152.73 Million
≈ $-1.65 Million
-0.263x -639.73%
2011-03-31 Rs910.26 Million
≈ $9.84 Million
Rs44.35 Million
≈ $479.64K
0.049x +16.28%
2010-03-31 Rs833.43 Million
≈ $9.01 Million
Rs34.92 Million
≈ $377.67K
0.042x +145.22%
2009-03-31 Rs918.65 Million
≈ $9.93 Million
Rs-85.13 Million
≈ $-920.63K
-0.093x -9.87%
2008-03-31 Rs845.93 Million
≈ $9.15 Million
Rs-71.35 Million
≈ $-771.58K
-0.084x -184.24%
2007-03-31 Rs691.60 Million
≈ $7.48 Million
Rs69.24 Million
≈ $748.82K
0.100x +155.05%
2006-03-31 Rs605.21 Million
≈ $6.55 Million
Rs23.76 Million
≈ $256.92K
0.039x --

About Themis Medicare Limited

NSE:THEMISMED India Drug Manufacturers - Specialty & Generic
Market Cap
$101.41 Million
Rs9.38 Billion INR
Market Cap Rank
#19223 Global
#1031 in India
Share Price
Rs101.81
Change (1 day)
-0.81%
52-Week Range
Rs66.07 - Rs142.46
All Time High
Rs300.15
About

Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic,… Read more